International Journal of Colorectal Disease

, Volume 28, Issue 3, pp 295–304

IBS and the role of otilonium bromide

  • Guy Boeckxstaens
  • Enrico S. Corazziari
  • Fermín Mearin
  • Jan Tack

DOI: 10.1007/s00384-012-1598-0

Cite this article as:
Boeckxstaens, G., Corazziari, E.S., Mearin, F. et al. Int J Colorectal Dis (2013) 28: 295. doi:10.1007/s00384-012-1598-0



Awareness of the seriousness of irritable bowel disorder (IBS) remains low among clinicians. In this review, we summarize the current knowledge of IBS and highlight the major personal, economic, and social burden of the disease, and the importance of adequate treatment of what is still often viewed as a trivial disorder. In fact, IBS is a major reason for referral.


It is crucial that the varied pathophysiologies of this complex heterogeneous disease are understood in order to be able to treat both the presenting symptoms (pain, bloating, flatulence, abnormal defecation, diarrhea, constipation) and the underlying disorder effectively. Low-grade inflammatory and immune activation has been observed, but the precise triggers and mechanisms, and the relevance to symptom generation, remain to be established.


IBS patients require different treatment strategies according to the pattern, severity, frequency, and symptoms. While initial therapy traditionally targets the most bothersome symptom, long-term therapy aims at maintaining symptom control and preventing recurrence. In addition to dietary/lifestyle interventions and psychosocial strategies, a wide range of pharmacologic therapies are approved for use in IBS depending on the symptoms reported. Musculotropic spasmolytics, which act directly on intestinal smooth muscle contractility, such as otilonium bromide, are effective, particularly in the relief of abdominal pain and bloating, and are well tolerated in IBS.

The OBIS trial

The recent large placebo-controlled Otilonium Bromide in Irritable Bowel Syndrome study demonstrated the superiority of otilonium bromide versus placebo not only in the reduction of pain and bloating, but also in protection from relapse due to the long-lasting effect.


Otilonium bromideIrritable bowel disorderSpasmolyticsIrritable bowel syndrome

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Guy Boeckxstaens
    • 1
  • Enrico S. Corazziari
    • 2
  • Fermín Mearin
    • 3
  • Jan Tack
    • 1
  1. 1.Department of Gastroenterology, Translational Research Center for Gastrointestinal Disorders (TARGID), University Hospital LeuvenCatholic University of LeuvenLeuvenBelgium
  2. 2.Department of Internal Medicine and Medical SpecialtiesUniversity La SapienzaRomeItaly
  3. 3.Institute of Functional and Motor Digestive DisordersCentro Medico TeknonBarcelonaSpain